Legacy Financial Group Inc. Has $204,000 Position in Eli Lilly and Company $LLY

Legacy Financial Group Inc. lessened its stake in Eli Lilly and Company (NYSE:LLY) by 30.6% during the 2nd quarter, Holdings Channel reports. The institutional investor owned 261 shares of the company’s stock after selling 115 shares during the quarter. Legacy Financial Group Inc.’s holdings in Eli Lilly and Company were worth $204,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in LLY. Brighton Jones LLC increased its position in Eli Lilly and Company by 22.0% in the 4th quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock worth $7,409,000 after purchasing an additional 1,730 shares during the last quarter. Revolve Wealth Partners LLC grew its stake in shares of Eli Lilly and Company by 2.8% in the 4th quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock valued at $1,136,000 after buying an additional 40 shares in the last quarter. Covestor Ltd grew its stake in shares of Eli Lilly and Company by 24.9% in the 1st quarter. Covestor Ltd now owns 426 shares of the company’s stock valued at $352,000 after buying an additional 85 shares in the last quarter. Kaufman Rossin Wealth LLC acquired a new position in Eli Lilly and Company in the first quarter worth approximately $242,000. Finally, Assetmark Inc. raised its position in Eli Lilly and Company by 5.6% during the first quarter. Assetmark Inc. now owns 44,978 shares of the company’s stock valued at $37,148,000 after acquiring an additional 2,383 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Trading Up 1.4%

Shares of NYSE:LLY opened at $1,058.05 on Friday. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $1,066.65. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. The company has a market cap of $1.00 trillion, a P/E ratio of 69.15, a P/E/G ratio of 1.21 and a beta of 0.43. The stock’s 50-day moving average is $855.89 and its 200-day moving average is $787.74.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, beating the consensus estimate of $6.42 by $0.60. The firm had revenue of $17.60 billion during the quarter, compared to the consensus estimate of $16.09 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The firm’s revenue for the quarter was up 53.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.18 EPS. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Equities research analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, December 10th. Investors of record on Friday, November 14th will be paid a dividend of $1.50 per share. This represents a $6.00 annualized dividend and a yield of 0.6%. The ex-dividend date is Friday, November 14th. Eli Lilly and Company’s dividend payout ratio is presently 29.35%.

Wall Street Analyst Weigh In

Several analysts have commented on LLY shares. Daiwa America downgraded shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research report on Sunday, August 17th. Daiwa Capital Markets lifted their price objective on shares of Eli Lilly and Company from $700.00 to $940.00 in a research note on Monday, November 10th. Berenberg Bank reissued a “hold” rating and set a $830.00 target price (down from $970.00) on shares of Eli Lilly and Company in a research report on Wednesday, September 17th. JPMorgan Chase & Co. boosted their price target on Eli Lilly and Company from $1,050.00 to $1,150.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 18th. Finally, Deutsche Bank Aktiengesellschaft decreased their price target on Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating for the company in a research note on Monday, August 11th. Three analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and seven have given a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $1,027.95.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.